25 results about "Phosphate buffered saline" patented technology

The invention discloses a method for detecting phenyl sulfide in rectification residual liquid of 2, 4-dichlorophenol through high performance liquid chromatography, and belongs to the technical field of chemical detection and analysis. The method comprises the following steps: dissolving a to-be-detected 2, 4-dichlorophenol rectification residual liquid sample to prepare a to-be-detected sample, and preparing phenyl sulfide standard substance solutions with different concentrations; the method comprises the following steps: determining a to-be-detected sample and a phenyl sulfide standard substance solution by adopting a high performance liquid chromatograph, drawing a standard curve and a linear regression equation according to a detection result of the phenyl sulfide standard substance solution, and analyzing the phenyl sulfide in the sample by combining the linear regression equation and a chromatographic peak map of the to-be-detected sample, wherein the mobile phase comprises a phase A and a phase B, the phase A is an aqueous solution of phosphate buffer salt, the phase B is methanol, and an isocratic elution mode is adopted. According to the present invention, with the method, the accurate determination of the phenyl sulfide content in the 2, 4-dichlorophenol rectification residual liquid is achieved, the timely and accurate data guidance is provided for the 2, 4-D production process, and the target of production cost saving is ultimately achieved.

The invention belongs to the technical field of resveratrol synthesis, and particularly relates to a preparation method of resveratrol and application of resveratrol in meat preservation. The method comprises the following steps: taking 3, 5-dimethoxybenzoic acid as a raw material, and carrying out acylation reaction to obtain 3, 5-dimethoxybenzoyl chloride. Then reacting with p-acetoxystyrene to generate 3, 3 '-dihydroxy-3, 3'-dihydroxy-3 The preparation method comprises the following steps: taking 1, 5-dimethoxy-4 '-acetoxystilbene as a raw material, hydrolyzing and demethylating to obtain resveratrol, and preparing resveratrol lipid nanoparticle suspension by taking resveratrol, a ZIF-8 / chitosan compound, compound lipid, cholesterol, epsilon-polylysine, ascorbyl palmitate and phosphate buffer saline as raw materials. High load and controlled release of resveratrol are achieved, and the problems that resveratrol is poor in water solubility and prone to oxidation are solved.

The present disclosure proposes a preparation method of a vesicle formed by an erythrocyte membrane encapsulating Newcastle disease virus, including: mixing a compacted erythrocyte solution, a phosphate buffered saline (PBS) solution, and Newcastle disease virus (NDV); centrifuging a resulting mixture of erythrocytes added with NDV; and resuspending and precipitating the centrifuged mixture with a PBS solution to obtain the vesicle formed by the erythrocyte membrane encapsulating Newcastle disease virus.

Provided is a reagent system for acridinium ester chemiluminescence, and a method of detecting a target antigen using the same. The reagent system for eliciting an acridinium ester chemiluminescence includes: a wash buffer including a first surfactant in one or more of a phosphate-buffered saline (PBS) and a tris-buffered saline (TBS); a first reagent including hydrogen peroxide and an acid, and optionally a first alkali metal salt; and a second reagent including a base and a second surfactant, and optionally a second alkali metal salt, where the first surfactant and the second surfactant are independently one or more of a cationic surfactant, a neutral surfactant and an anionic surfactant, where the acid having an acid dissociation constant (pKa) of −1.0 to 5.0, and where the base comprises one or more of sodium hydroxide (NaOH), potassium hydroxide (KOH), ammonium hydroxide, tetra-n-ethylammonium hydroxide (TEA), tetra-n-propylammonium hydroxide (TPA), and tetra-n-butylammonium hydroxide (TBA).

This invention discloses an interpenetrating network antibacterial hydrogel with angiogenesis function, its preparation method, and its applications. The hydrogel is formed by in-situ photocrosslinking of a precursor solution to create a three-dimensional interpenetrating network structure. The precursor solution comprises the following components by mass fraction: 0.5%–1.5% gallic acid-modified low-viscosity chitosan, 0.5%–1.5% decellularized liver matrix, 8%–12% methacrylic acid gelatin, 0.5%–1.0% photoinitiator, and the balance being phosphate-buffered saline. This invention uses low-viscosity chitosan as the modifying unit, combined with a strategy of precise acid adjustment before blending. This not only effectively avoids the risks of polymer phase separation and flocculation that are easily caused during multi-component blending, but also fundamentally solves the problem of the influence of the acidic microenvironment on the interpenetrating crosslinking of polymers. The precursor solution of this hydrogel has excellent fluidity, can precisely adapt to irregular defects, and can solidify rapidly in situ. It integrates antibacterial properties and induces angiogenesis, showing broad application prospects in the repair of complex skin tissues such as chronic diabetic wounds.

A method of preparing a FeMnCeOx biomaterial is provided, including the following steps. A Pseudomonas sp. strain KW-2 is obtained. A culture medium with a pH of 6.5-7.8 is prepared, which includes 0.1 g / L K2HPO4, 0.2 g / L MnSO4·7H2O, 0.2 g / L NaNO3, 0.1 g / L CaCl2), 0.1 g / L NH4Cl, 0.1 g / L (NH4)2CO3, 35 g / L NaCl and 150 mg / L ferric ammonium citrate. The culture medium is autoclaved, inoculated with the KW-2 strain, cultured for 1-3 days, added with a cerium nitrate solution, cultured for 3-7 days and centrifuged at 4,000-8,000 rpm for 10-20 min to collect a precipitate. The precipitate is rinsed 5-8 times with deionized water and 0.01 mol / L phosphate buffered saline (PBS) and freeze-dried at −60° C. to obtain the FeMnCeOx biomaterial. A method for treating antibiotic wastewater using the FeMnCeOx biomaterial is also provided.

The present disclosure relates to a process to assemble proteins derived from platelet lysates in bioactive microparticles, with increased surface organization. The present invention further relates to protein-based biomaterials applicable to biomedical and biotechnology fields, more precisely in tissue engineering strategies, disease modeling, and other biomedical applications. Namely, a method for obtaining a protein microparticle from a platelet lysate comprising the following steps: lyophilizing the platelet lysate; dissolving the lyophilized platelet lysate in phosphate buffer saline to obtain a platelet lysate solution; adding a reducing agent to the platelet lysate solution to obtain a reduced platelet lysate solution; adding an oxidizing agent to the reduced platelet lysate solution to form the microparticles by precipitation.

The present application provides a visible light crosslinking composite gel type hemostatic dressing, comprising 1-55% methacrylated natural polymer, 0.0001-0.05% visible light initiator, 2-15% thickening agent; the method for preparing the hemostatic dressing comprises the following steps: firstly, preparing a visible light initiator solution, and dissolving the methacrylated natural polymer with the visible light initiator solution to obtain solution A; dissolving the thickening agent with deionized water or a phosphate buffered saline solution to obtain solution B; uniformly mixing solution A and solution B to obtain the visible light crosslinking composite gel type hemostatic dressing. The present application (1) is suitable for first aid hemostasis; (2) is solidified under visible light irradiation and closely adheres to the wound tissue; (3) has good adhesion, flexibility and moisturizing property after being solidified under visible light irradiation, and has a certain healing promotion effect.

The invention discloses a preparation method of a soybean seed coat polysaccharide encapsulated essential oil liposome antibacterial agent, which comprises the following steps: uniformly dispersing soybean lecithin (20mg / ml), stigmasterol (4mg / ml) and essential oil (1%) in absolute ethyl alcohol, carrying out rotary evaporation at 45 DEG C until a uniform lipid film is formed in a bottle, transferring into a vacuum drying oven, and further drying and removing ethyl alcohol; the method comprises the following steps: carrying out ultrasonic treatment on a liposome sample, hydrating by using a phosphate buffer solution (PBS, 0.01 mol / l, pH of 7.2-7.4) containing Tween-80, and carrying out ultrasonic treatment for 10 minutes under the power of 200W to obtain the liposome sample; uniformly mixing the soybean seed coat polysaccharide solution (0.01%-0.2%) with the liposome solution according to the volume ratio of 1: 1, and stirring for 1 hour to obtain a soybean seed coat polysaccharide encapsulated liposome solution; the slow-release antibacterial agent prepared by the preparation method disclosed by the invention has excellent slow-release effect and antibacterial property, and the preparation method is simple to operate and low in cost.

The application relates to the technical field of medical biomaterials, in particular to a nanofiber composite hydrogel gastrointestinal patch and a preparation method thereof, which comprises the following steps: dissolving polycaprolactone in trifluoroethanol to obtain solution A; dispersing T-5224 in the solution A, uniformly mixing and then performing electrospinning to obtain a nanofiber membrane; adding carboxymethyl chitosan into a phosphate buffered saline solution, stirring until completely dissolved to obtain an A-component solution; sequentially adding sodium alginate oxide and tannic acid into the phosphate buffered saline solution, stirring until completely dissolved to obtain a B-component solution; mixing the A-component solution and the B-component solution in proportion, uniformly stirring, then smearing the mixture on the surface of the nanofiber membrane, and standing until the hydrogel is formed to obtain the nanofiber composite hydrogel gastrointestinal patch. In the application, the nanofiber membrane is used as a substrate, the hydrogel coating layer is crosslinked to form a stable three-dimensional network structure, and the mechanical property of the overall patch can meet the support requirement in the gastrointestinal repair process.

Disclosed herein are polymeric nanoparticles containing peptides, which provide low burst release and sustained, delivery of the peptides, and pharmaceutical compositions thereof. The polymeric nanoparticles contain a peptide encapsulated or dispersed therein. The nanoparticles can provide sustained release of the peptide, for example, less than 20% of the peptide is released initially (at time 0 hour) following placement into a phosphate buffered saline at pH 7.4 at 37° C. and room pressure. Methods for micronizing a peptide and for preparing polymeric nanoparticles containing solid, micronized peptides are also disclosed. The preparation methods use miscible solvent and non-solvent pairs in phase inversion nanoencapsulation processes. The Gibbs energy of mixing (ΔGMix) between the solvent and non-solvent can be tailored to achieve desired particle size, encapsulation efficiency, and release profile.

The invention discloses a treatment method for strengthening active components of medicinal and edible medicinal materials, which comprises the following steps: adding a phosphoric acid buffer salt solution and cellulose compound enzyme into medicine residue thick slurry, carrying out enzymolysis reaction for 2-8 hours in an acid environment of 45-55 DEG C by adopting ultrasonic oscillation, and collecting enzymatic hydrolysate; or performing particle crushing and homogenizing treatment by using the pressure of 30-60MPa, performing 2-10 times of volume circulation treatment capacity, performing oscillation treatment on the cell crushing liquid by using 30-80W ultrasonic waves, and collecting filtrate; performing differential centrifugation on the enzymatic hydrolysate or / and the filtrate to obtain an exosome solution; and adding the exosome solution into the concentrated original liquid medicine, and stirring and heating at 80-90 DEG C for 30-60 minutes. Residual cell exosomes are extracted from medicine residues of medicinal and edible medicinal materials and added into original Chinese herbal medicine liquid, Maillard reaction is carried out through heat treatment, and the oxidation resistance of the raw medicinal materials can be improved by 15% or above.

This invention discloses a tannic acid-reinforced anisotropic polyvinyl alcohol hydrogel, its preparation method, and its applications. The preparation method of the hydrogel includes: subjecting the polyvinyl alcohol hydrogel to sequential mechanical stretching, salting-out fixation, freeze-drying, and annealing to construct an anisotropic structure, followed by immersion in a tannic acid solution for reinforcement. The hydrogel exhibits high crystallinity, excellent mechanical properties, and an extremely low equilibrium swelling rate, with a swelling rate of only 4.8% in phosphate buffered saline. The introduction of tannic acid endows the hydrogel with broad-spectrum antibacterial, antioxidant, and anti-inflammatory functions. The anisotropic structure, in conjunction with tannic acid, can significantly promote the directional migration of endothelial cells, angiogenesis, and the orderly regeneration of epithelium and smooth muscle. Animal experimental results show that this hydrogel can effectively reduce the recurrence rate of urethral stricture and achieve scarless functional repair.

The invention discloses cell-free fat extract loaded GelMA hydrogel and skin flap survival application, and particularly relates to the technical field of biomedical engineering. The hydrogel is prepared from GelMA, Ceffe, lithium phenyl (2, 4, 6-trimethylbenzoyl) phosphonate and a phosphate buffer salt solution. Wherein the Ceffe is rich in a plurality of angiogenesis promoting factors and is obtained through physical emulsification and centrifugal extraction; gelMA is prepared by modifying pig A-type gelatin through methacrylic anhydride, and has temperature-sensitive and photo-crosslinking characteristics. The injectable hydrogel with a porous network structure is formed by mixing Ceffe and a GelMA solution and curing through ultraviolet irradiation. The compound system realizes Ceffe biphasic slow release, remarkably promotes proliferation, migration and tube formation of vascular endothelial cells in vivo and in vitro, improves the survival rate of random skin flaps of mice, and effectively relieves oxidative stress injury caused by ischemia reperfusion by up-regulating HO-1 and down-regulating INOS.

Described herein are formulations of a peptide derived from Chaperonin 60.1 suitable for sublingual administration. A dissolvable tablet pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This dissolvable tablet formulation includes a matrix-forming agent, a surfactant, a pH modifier, and a solvent. It may also contain sweeteners, flavor enhancers, or flavoring agents. In addition, a liquid pharmaceutical formulation is designed for sublingual administration of a Chaperonin 60.1-derived peptide. This liquid pharmaceutical formulation includes the peptide, bovine serum albumin, and phosphate-buffered saline. The sublingual formulations achieve rapid systemic delivery comparable to IV administration. These formulations are intended for treating inflammatory conditions through sublingual administration. The formulations can be used for various inflammatory conditions and are adaptable for different administration frequencies and subject types.

The application provides a composite preservative for fecal microorganisms and metabolites thereof and a same-tube multi-omics joint detection integrated technology. The composite preservative contains main components of cetyltrimethylammonium bromide (CTAB), ammonium chloride (NH4Cl) and phosphate buffered saline (PBS), can keep the stability of microorganisms and metabolites thereof in a fecal sample during storage and transportation at room temperature, and guarantees the extraction efficiency of deoxyribonucleic acid (DNA) of the microorganisms in the fecal sample. The application also eliminates the influence of the preservative components on metabolite detection by adding a treatment reagent, significantly improves the response and ionization efficiency of the fecal sample metabolites in mass spectrometry, and thus improves the sensitivity and accuracy of the detection results. The application not only solves the timeliness problem of fecal sampling, but also provides a technical basis and idea for the feasibility study of the same-tube multi-omics of the fecal sample, and has a broad research and clinical application prospect.

A kit for the detection of Helicobacter pylori antibody in an oral exudate is provided. The kit includes an antigen and a diluent for diluting the oral exudate. The antigen is Helicobacter pylori HpC-025 with the deposit registration number of CCTCC No: M20221024. The diluent contains phosphate buffered saline (PBS), casein, surfactant Tetronic 1307, and surfactant RHODASURF® ON-870. The kit may also include, a sampling swab, a collection tube, a plate cartridge, and a test strip with a binding pad bound with latex microspheres labeled with the Helicobacter pylori HpC-025 antigen.

According to the method for separating the CD34 < + > hematopoietic stem cells from the umbilical cord blood, the nonspecific clearance rate of the CD34 < + > cells is reduced by reducing the dosage of a RosetteSep antibody; the ratio of the RosetteSep antibody to the CD34 positive antibody to the magnetic beads is optimized; the albuginea layer containing CD34 + cells and a part of density gradient centrifugate below the albuginea layer are absorbed in a whole interval, and loss of CD34 + hematopoietic stem cells is avoided; determining the standardized dilution ratio of the phosphate buffer saline, and eliminating the influence of the lymphocyte separation medium with high buoyancy density on the sedimentation separation of the stem cells; the centrifugal rate after the phosphate buffer saline is diluted and the acceleration of speed increase and speed reduction in the centrifugal process are optimized, so that complete precipitation of CD34 + cells is ensured, and mechanical damage is reduced; and multiple measures are coordinated and matched, so that the separation efficiency of the CD34 + hematopoietic stem cells is improved, the purity is improved, and the separation cost is reduced.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a separation and determination method of an esculentin hydrochloride intermediate K5 and related impurities thereof. The impurities comprise one or more of S-tert-butyl sulfinamide, an impurity K4a, an impurity K4, benzyl chloride, an impurity K3 and toluene. The method comprises the following steps: a chromatographic column adopts octadecylsilane chemically bonded silica as a filler, a mobile phase comprises a mobile phase A and a mobile phase B, and the mobile phase A and the mobile phase B are both mixed solutions of a phosphoric acid buffer salt solution and acetonitrile; in the mobile phase A, the volume ratio of the phosphoric acid buffer salt solution to the acetonitrile is (50-70): (50-30); in the mobile phase B, the volume ratio of the phosphoric acid buffer salt solution to the acetonitrile is (20-40): (80-60); separating through linear gradient elution, then detecting in a detector to obtain a chromatogram, and calculating the content of each impurity by adopting an external standard method. The method has the characteristics of good separation degree, good durability, high sensitivity and good reproducibility.

A method of assessing drug cardiac safety using human stem cell-derived cardiomyocytes, includes: step (A) of preparing cardiomyocytes by culturing human stem cells to differentiate into cardiomyocytes; step (B) of diluting fibronectin in DPBS (Dulbecco's phosphate buffered saline) at a concentration of 50 μg / ml; step (C) of adding the fibronectin solution, obtained by diluting to the concentration of 50 μg / ml in step (B); step (D) of placing the MEA plate; step (E) of removing the fibronectin solution from specific wells of the MEA plate; step (F) of adding a predetermined medium to the specific wells of the MEA plate; and step (G) of measuring changes in information values about beat rate, spike amplitude and field potential duration depending on whether a drug to be assessed has been added to the wells of the MEA plate.

The application relates to the technical field of biomaterials, and discloses a high-biocompatibility hydrogel based on enzyme catalysis cross-linking and a preparation method thereof, which comprises the following steps: mixing a polypeptide mother liquor containing a tyrosine residue, functional nanoparticle tyrosinase and an MES buffer solution to obtain precursor solution A; mixing gelatin, recombinant elastin and a phosphate buffered saline solution to obtain a polymer mother liquor, and adding microbial transglutaminase into the polymer mother liquor to obtain precursor solution B; and mixing and reacting the precursor solution A and the precursor solution B to obtain the high-biocompatibility hydrogel based on enzyme catalysis cross-linking. In the application, the interpenetrating network constructed by the tyrosinase and the microbial transglutaminase sequentially catalyzes a significant synergistic enhancement effect. In a hyperglycemic environment, a mesoporous silica nanoparticle built-in level connection system is automatically activated, realizing multiple effects of antibiosis, anti-inflammation and promotion of angiogenesis.

The application discloses a Hashimoto's thyroiditis model, a construction method thereof and an antigen, and the construction method comprises the following steps: preparing a pig thyroid lyophilized powder; selecting 8-week-old EAT susceptible strain CBA / J female mice, and injecting phosphate buffered saline solutions containing the pig thyroid lyophilized powder at the 0th day, the 7th day and the 14th day after 8 weeks; injecting phosphate buffered saline solutions containing lipopolysaccharide at a predetermined time interval; when the EAT susceptible strain CBA / J female mice are 12 weeks old, the modeling effect is measured from thyroid pathological morphology and EAT scores, serum TgAb concentration, serum TPOAb concentration and the number of each T lymphocyte subpopulation in the spleen. After the mice are continuously injected with the phosphate buffered saline solutions containing the pig thyroid lyophilized powder and the lipopolysaccharide for three times through the tail vein, the mice produce autoantibodies, and obvious lymphatic infiltration appears in the thyroid tissue, which indicates that the pig thyroid lyophilized powder can induce the occurrence of Hashimoto's thyroiditis, and a new thought is provided for the pathogenesis of Hashimoto's thyroiditis.

A process for the methacrylation of dECM comprises placing a carbonate buffer at a concentration of 1 M into a reaction vessel and heating to a temperature of 50 DEG C, adding dECM to the carbonate buffer to obtain a dECM solution at a concentration of 4% (w / v), sterilizing the solution by irradiation with radiant ultraviolet rays for 15 minutes, adding methacrylic anhydride in an amount of 0.5 mL / 1 g of dECM and reacting at 50 DEG C for 1 hour, and then removing the dECM from the reaction vessel. Then adding a phosphate buffer salt solution to obtain a diluent which is 5 times of the mixture, putting the obtained solution into a dialysis tube, then putting the dialysis tube into deionized water, carrying out the stage at 40 DEG C for not more than 4 days, after the stage is completed, transferring the solution in the dialysis tube into an aluminum plate, and then standing at-80 DEG C for at least 3 hours, and then freeze-drying the frozen solution under the following conditions: the shelf temperature is 10 DEG C, the pressure is 0.1 mba, and the freeze-drying time is 48 hours. The invention also relates to the methacrylated dECM obtained by the above process, and to the use of the methacrylated dECM obtained by the above process in a bioprinting process.

The application discloses a carbon-based molecular brush lymphatic nano-tracer and a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: preparing a nanosphere precursor and carbonizing the nanosphere precursor into carbon nanospheres, or directly selecting nanometer carbon black, superfine carbon powder and the like; grafting a hydrophilic polymer side chain to the carbon nanometer particles after pretreatment, so as to obtain carbon-based molecular brush nanometer particles; and dispersing the carbon-based molecular brush nanometer particles in normal saline or a phosphate buffered saline solution, so as to obtain the carbon-based molecular brush lymphatic nano-tracer. The carbon nanometer particles and the hydrophilic polymer side chain can be covalently combined, the intrinsic hydrophilic carbon-based molecular brush nanometer particles are endowed with persistent and stable monodisperse performance in normal saline and injected biological tissues, and as the lymphatic nano-tracer, the carbon-based molecular brush lymphatic nano-tracer is expected to be applied to rapid tracing and imaging of lymph nodes, and has wide application prospects and great market value.

The present application belongs to the technical field of traditional Chinese medicine detection, and particularly relates to a content detection method of effective components in Goutongling tincture. The present application aims to provide a content detection method of effective components in Goutongling tincture, which comprises the following steps: a, preparation of test sample solution: a certain amount of Goutongling tincture is loaded on an activated solid phase extraction column, eluted, washed, eluted, collected, evaporated, diluted, filtered, and then a continuous filtrate is obtained; b, preparation of control sample solution; c, chromatographic conditions: octadecylsilane-bonded silica gel is used as a filler, acetonitrile and phosphate buffered saline solution are used as mobile phases for gradient elution, the detection wavelength is 210 nm, the column temperature is 25-40 DEG C, the flow rate is 0.25-1.0 mL / min; and d, determination method: the control sample solution and the test sample solution are precisely taken respectively, injected into a high performance liquid chromatograph, and determined, and then the content detection method of effective components in Goutongling tincture is obtained. The method is simple and easy to operate, time-saving, and solves the problem of few quality control indicators.